X @The Wall Street Journal
The Wall Street Journal·2026-05-12 13:37
The drugmaker’s on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said. https://t.co/gimMaaZMnC ...